PD-L1 expression by tumor cell lines: A predictive marker in melanoma

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Prognostic biomarkers are crucial for identifying melanoma patients who may benefit from adjuvant therapy after lymph node resection.
• Accurate prediction of relapse risk in stage III melanoma is essential for personalized treatment strategies.

Purpose of the Study:

• To investigate the prognostic relevance of immune-related biomarkers, including MHC-class I and II, melanoma-associated antigens, Indoleamine 2,3-dioxygenase 1 (IDO1), and Programmed Death-Ligand 1 (PD-L1).
• To determine if these biomarkers can predict the risk of relapse in stage III melanoma patients post-lymph node resection using an in vitro model.

Main Methods:

• Establishment of melanoma cell lines from metastatic lymph nodes of 50 patients.
• Assessment of biomarker expression (MHC-class I/II, antigens, IDO1, PD-L1) on cell lines using flow cytometry.
• Analysis of biomarker expression in both untreated and interferon-gamma (IFN-γ) treated conditions.

Main Results:

• The IFN-γ-induced expression of PD-L1 was significantly associated with an increased risk of melanoma relapse (P = .0001).
• The IFN-γ-induced expression of IDO1 was also linked to a higher risk of relapse (P = .013) and mortality (P = .0005).
• MHC-class I/II and melanoma-associated antigens did not show significant association with relapse risk in this cohort.

Conclusions:

• IFN-γ-induced PD-L1 and IDO1 expression serve as potential prognostic biomarkers for melanoma relapse after lymph node resection.
• This immunologic signature could identify high-risk patients eligible for adjuvant immunotherapy.
• Further validation is needed to integrate these biomarkers into clinical decision-making for melanoma treatment.